Keywords
How to Cite
Abstract
COVID 19 pandemia produced a drastic change in our lifestyles, perspectives, and concerns. In the field of Thrombosis and Haemostasis, a great amount of information was published; however, a loss of certainty invaded our medical daily work, including well-stablished practices for anticoagulation.This article describes some of the new information gathered as well as early provisional recommendations of International Scientific Societies and personal opinions taking into account the first 18 months of dealing with the SARS-COV2 virus.
References
2. Roubinian NH, Dusendang JR, Mark DG et al. JAMA Intern Med. April 5, 2021. doi:10.1001/jamainternmed.2021.0488.
3. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Research and Practice in Thrombosis and Haemostasis. 2020;4(7):1178-1191.
4. Lopes RD, Melo de Barros e Silva PG, Furtado RHM et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021; 397: 2253-63.
5. Paranjpe I, Fuster V, Lala A et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival
Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020; 76(1):122-124.
6. Vaughn VM, Yost M, Abshire Ch et al. Trends in venous thromboembolism anticoagulation in patients
hospitalized with COVID 19. JAMA Network Open. 2021; 4 (6): e2111788.doi:10.1001/jamanetworkopen.2021.11788
7. Giannis D, Allen SL, Tsang, J, Flint S, Pinhasov T et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838-2847.
8. Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020; 136(11): 1347-1360.
9. Talasaz AH , Sadeghipour P, Kakavand H et al. Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials.
medRxiv preprint doi: https://doi.org/10.1101/2021.0 1.04.21249227.
10. Testa S, Prandoni P, Paoletti O et al. Direct oral anticoagulant plasma levels striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents. The Cremona experience J Thromb Haemost. 2020; 00:1-4 . doi: 10.1111/JTH.14871.
11. HS England/ NHS Improvement: Clinical guide for the management of anticoagulant services during the coronavirus pandemic. Last updated February 2021.
12. Testa S, Paoletti O, Giorgi-Pierfranceschi M. Switch from oral anticoagulants to parenteral heparin in SARS-COV-2 hospitalized patients. Internal and Emergency Medicine. 2020. https://doi.org/10.1007/s11739-020-02331-1.
13. Weeks LD, Sylvester KW, Connors JM et al. Res Pract Thromb Haemost. 2021; 00 : e12521. doi.org/10.1002/rth2.12521.
14. Barnes GD, Burnett A, Allen A et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020; 50:72-81.
15. Spyropoulos AC, Levy JH, Ageno W et al. Scientific and Standardization Committee communication:
Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.
16. Schutgens RE. HemaSphere (2021) 5:1(e526). http://dx.doi.org/ 10.1097 www.covid19treatmentguidelines.nih.gov
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar